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OBJECTIVES: To provide health care to hemophiliacs is
the result of a complex interaction between different
patients, physicians, policy-makers, etc., carrying their
individual sets of preferences, the precise understanding
of which is of great utility in planning of optimal care.
This study investigates preferences on hemophilia care in
212 adult Italian severe and moderate hemophiliacs by
means of a quantitative method called conjoint analysis.
This technique shows how individuals are willing to trade
between different characteristics. Consequently it pro-
duces overall beneﬁt scores for alternative ways of pro-
viding health care and estimates the relative importance
of different characteristics of a service. METHODS: Con-
joint analysis was used with a discrete choice design.
Respondents were asked to choose between two different
scenarios as combination of attributes and levels previ-
ously identiﬁed by asking patients and physicians, in 16
pair-wise comparisons. Attributes and levels were: viral
safety (as that provided by highly puriﬁed double inacti-
vation plasma derived versus recombinant concentrates),
development of inhibitors (3 levels: 30%, 20%, 10%),
half-life (deﬁned by number of administrations per week
for prophylaxis: 3, 2, and 1 infusions weekly), ease of use
(powder to dilute or ready-to-use solution), distribution
(home, local pharmacy, hospital) and price. RESULTS: Of
209 patients who completed the questionnaire, 31 were
excluded because they inconsistently answered to a pur-
posely included scenario. Overall 178 patients’ responses
were evaluated. All attributes considered, excluding ease
of use, tested important to respondents. Patients showed
a strong preference toward both outcome variables (viral
safety, risk of development of inhibitors) and process 
variables (distribution, half-life). CONCLUSIONS: Our
study ﬁrst applied conjoint analysis to elicit preferences
toward hemophilia care. Our estimates provide evidence
of the importance of patients’ preferences in the whole
process of health care providing. These results might
guide physicians and policy-makers in planning the
optimal hemophilia treatment.
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Clinical studies have shown signiﬁcant improvements in
outcomes with the use of prophylactic haemophilia treat-
ment compared to on-demand treatment. Further analy-
ses showed that health-related quality of life could be
maintained with prophylactic treatment. So far rare data
on utility values exist. OBJECTIVE: The purpose of this
analysis was to derive patient preferences measured in
utilities and health related quality of life associated with
on-demand and prophylactic therapy of haemophilia
patients in Sweden, the United Kingdom, the Netherlands
and Germany. METHODS: Analysis was based on data
collected by the European Haemophilia Economic Study
Group. Utilities were derived by using a preference-based
algorithm to transform the SF-36 into a single SF-6D
index. Equations for predicting mean utilities in different
patient subgroups were derived by using multiple regres-
sion analysis. RESULTS: A total of 506 patients was
included. Patients receiving prophylactic treatment had
higher mean utilities than patients receiving on-demand
(>30yrs: 0.68 vs. 0.66, p = 0.15; 30yrs: 0.76 vs. 0.73, p
= 0.02). Stratiﬁcation by HIV-infection showed that the
utility gain with prophylactic treatment was higher in
HIV-negative patients (prophylaxis: 0.73, on demand:
0.68; p < 0.0001) compared to HIV-positive patients
(prophylaxis: 0.69; on demand: 0.68; p = 0.67). There
was an association between utilities, annual number of
joint bleeds and the physical examination score (PES):
with increasing number of joint bleeds per year, utilities
decreased and PES increased. Health-related quality of
life was strongly inﬂuenced by patients’ age. Main pre-
dictors for quality of life were occurrence of disability,
HIV- or hepatitis B infection, average amount of clotting
factor, number of bleedings per year and physical exam-
ination score. CONCLUSION: Patient preferences vary
between different patient subgroups and the results are
sensitive to age and co-morbidity. Further research should
include a long-term prospective quality of life measure-
ment with patients receiving primary prophylaxis and on-
demand treatment.
